GlobeNewswire: Larimar Therapeutics, Inc. Contains the last 10 of 146 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T23:22:05ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/12/15/2145316/0/en/Larimar-Therapeutics-Added-to-NASDAQ-Biotechnology-Index.html?f=22&fvtc=4&fvtv=22232Larimar Therapeutics Added to NASDAQ Biotechnology Index2020-12-15T13:00:00Z<![CDATA[BALA CYNWYD, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.]]>https://www.globenewswire.com/news-release/2020/12/08/2141232/0/en/Larimar-Therapeutics-Announces-Completion-of-Dosing-of-the-Single-Ascending-Dose-Clinical-Trial-in-Friedreich-s-Ataxia-Patients-and-Provides-Program-Update.html?f=22&fvtc=4&fvtv=22232Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update2020-12-08T12:30:00Z<![CDATA[- Preliminary data suggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg]]>https://www.globenewswire.com/news-release/2020/11/13/2126473/0/en/Larimar-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=22232Larimar Therapeutics to Participate in Upcoming Investor Conferences2020-11-13T13:00:00Z<![CDATA[BALA CYNWYD, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will participate in 1x1 investor meetings at the virtual Guggenheim Securities Healthcare Talks. Additionally, Dr. Ben-Maimon will present a fireside chat and participate in 1x1 investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference. See below for more details.]]>https://www.globenewswire.com/news-release/2020/11/10/2123717/0/en/Larimar-Therapeutics-Reports-Third-Quarter-2020-Operating-and-Financial-Results.html?f=22&fvtc=4&fvtv=22232Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results2020-11-10T13:00:00Z<![CDATA[Phase 1 trials evaluating CTI-1601 as a treatment for Friedreich’s ataxia on track for topline data in 1H 2021]]>https://www.globenewswire.com/news-release/2020/10/13/2107467/0/en/Larimar-Therapeutics-Announces-Formation-of-Scientific-Advisory-Board.html?f=22&fvtc=4&fvtv=22232Larimar Therapeutics Announces Formation of Scientific Advisory Board2020-10-13T12:00:00Z<![CDATA[BALA CYNWYD, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the formation of its Scientific Advisory Board (SAB). Larimar’s SAB is comprised of distinguished research scientists, professors and industry experts recognized as key opinion leaders in the fields of rare disease, pediatrics and mitochondrial disease.]]>https://www.globenewswire.com/news-release/2020/09/21/2096612/0/en/Larimar-Therapeutics-to-Present-at-the-Oppenheimer-Fall-Healthcare-Life-Sciences-MedTech-Summit.html?f=22&fvtc=4&fvtv=22232Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit2020-09-21T13:58:24Z<![CDATA[BALA CYNWYD, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21, 2020, at 1:40 p.m. EDT.]]>https://www.globenewswire.com/news-release/2020/09/10/2091649/0/en/Larimar-Therapeutics-to-Present-at-the-Morgan-Stanley-Virtual-18th-Annual-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=22232Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference2020-09-10T12:00:00Z<![CDATA[BALA CYNWYD, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Thursday, September 17, 2020, at 11:45 a.m. EDT.]]>https://www.globenewswire.com/news-release/2020/08/11/2076240/0/en/Larimar-Therapeutics-Reports-Second-Quarter-2020-Operating-and-Financial-Results.html?f=22&fvtc=4&fvtv=22232Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results2020-08-11T11:00:00Z<![CDATA[BALA CYNWYD, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2020 operating and financial results.]]>https://www.globenewswire.com/news-release/2020/08/04/2072436/0/en/Larimar-Therapeutics-to-Present-at-the-2020-Wedbush-PacGrow-Healthcare-Conference.html?f=22&fvtc=4&fvtv=22232Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference2020-08-04T12:00:00Z<![CDATA[BALA CYNWYD, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020, at 8:35 a.m. EDT.]]>https://www.globenewswire.com/news-release/2020/07/28/2068625/0/en/Larimar-Therapeutics-Announces-Positive-Opinion-on-Orphan-Drug-Designation-Received-from-the-European-Medicines-Agency-for-CTI-1601-for-the-Treatment-of-Friedreich-s-Ataxia.html?f=22&fvtc=4&fvtv=22232Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia2020-07-28T12:00:00Z<![CDATA[BALA CYNWYD, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the company’s application for orphan drug designation for CTI-1601, a potential treatment for Friedreich’s ataxia (FA), a rare, progressive, multi-symptom genetic disease that affects the functioning of multiple organs and systems. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with FA who are unable to produce enough of this essential protein. The U.S. Food and Drug Administration (FDA) previously granted Orphan Drug, Fast Track and Rare Pediatric Disease designations to CTI-1601 for the treatment of FA. Larimar expects that the European Commission, based on this positive opinion of the COMP, will formally grant the orphan drug designation for the European Union (EU) this year.]]>